Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

2D illustration showing scientists' hands editing a DNA strand

Gene editing

Startup Aurora Seeks To Replicate Baby KJ Success With $16M in Seed Money

Aurora joins the clutch of companies linked to Nobel Prize winner and CRISPR trailblazer Jennifer Doudna.

January 12, 2026

2 min read

Tristan Manalac

Water tap dripping dollar bills on gray background. Business and financial success concept. 3D Rendering

IPO

Veradermics, Eikon Eye Public Market Debut as IPO Tap Opens

Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 million IPO target.

January 12, 2026

2 min read

Tristan Manalac

Policy

Flagship CEO Calls Out Attacks on Science, Warns of China Dominance

In his annual letter, Flagship Pioneering’s Noubar Afeyan lays out a choice between near-term “human-made miracles” and a reversion to the pain and suffering of past diseases due to “growing contempt” in the U.S. for the scientific method.

January 12, 2026

4 min read

Heather McKenzie

Distorted pink piggy bank squeezed in vise , symbolizing financial stress and debt. with plain blue background

Venture capital

Early-Stage Biotechs Feel the Squeeze as Funding Favors Derisked Assets: JPM

Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P. Morgan found in a report published ahead of the bank’s annual healthcare conference in San Francisco.

January 12, 2026

2 min read

Nick Paul Taylor

Medical dropper system with bag on tube 3d vector illustration. Advertising poster with laboratory equipment over copy space. Hospital emergency services promotion

Opinion

To Broaden Access to CAR Ts, Mitigate Their Side Effects

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome limits the reach of these transformative cancer therapies.

January 12, 2026

4 min read

Teresa Whalen

Isometric Digital marketing strategy web banner concept. Analysis data cloud and Investment landing page. Media Technology

FDA

6 FDA Decisions To Watch in Q1 2026

After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after being delayed from the fourth quarter last year.

January 12, 2026

8 min read

Tristan Manalac

Drug Development

Biopharma Momentum To Propel Rare Disease, Cancer, Neuro Forward in 2026

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told BioSpace, with both rare and chronic diseases headlining investor and R&D interest as JPM26 kicks off.

January 12, 2026

6 min read

Heather McKenzie